VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Annexin-Vivo 750 imaging agent for measuring and monitoring apoptosis and cell death in vivo. The new Annexin-Vivo 750 agent is based on the well established Annexin labeling standard in in vitro research. It is expected to significantly expand research areas and enhance drug development by enabling real time imaging of apoptosis and cell death biomarkers associated with disease progression and therapeutic response in vivo.
Annexin-Vivo 750 targets membrane-bound phosphatidylserine exposed in the outer leaflet of the plasma membrane during the induction of apoptosis and cell death. The new agent was developed through an R&D collaboration with MosaMedix, a pioneer in the development of advanced Annexin V-based products. "Annexin is a gold standard in research for the detection of exposed phosphatidylserine, a hallmark of apoptotic and dying cells," said Kirtland Poss, VisEn's President and CEO. "VisEn and MosaMedix have worked closely together to develop a robust Annexin-based in vivo fluorescent imaging agent for the assessment of apoptosis and cell death in vivo. We expect this agent to open up truly breakthrough research areas, especially along with complementary in vitro readouts and within VisEn's broader fluorescence in vivo imaging agent portfolio." "We are extremely pleased to be working with VisEn, a clear leader in the field of in vivo fluorescent imaging and the perfect partner in enabling the new in vivo imaging applications using our Annexin V technology platforms," said Peter Moonen, CEO of MosaMedix.